Avid Bioservices Inc (CDMO)

[Fire Fox]

Excellent point WH-- Given that we know PS is exposed on HCV virons and infected cells in the same way it is exposed on the VHF virons and infected cells, it seems Bavi would have the same additive effect to ribavirin in the HCV environment that it has in the VHF environment.

I'm sure you are right in saying this is why SK finds today's VHF data so "encouraging and relevant" to the upcoming new HCV trial.

Given the company's limited funds and primary focus on cancer, your speculation makes sense that the next HCV trial is likely to be done with a strategic partner.